Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs

Experimental Hematology

Volumn 38, Issue 10, 2010, Pages

  Isakova, Iryna A ^a   Dufour, Jason ^b   Lanclos, Calvin ^b   Bruhn, Julie ^b   Phinney, Donald G ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CD16+ T LYMPHOCYTE; CD28+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HAPLOTYPE; IMMUNOGENICITY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL COUNT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

ANIMALIA; MACACA MULATTA;

EID: 77956618495     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.06.011     Document Type: Article

References (48)

1. Uccelli A., Moretta L., Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006, 36:2566-2573.
2. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft in vivo. Exp Hematol 2002, 30:42-48.
3. Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
4. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
5. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
6. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
7. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005, 305:33-41.
8. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune responses. Blood 2005, 105:1815-1822.
9. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone-marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
10. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immuno-suppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
11. Eliopoulos N., Stagg J., Lejeune L., Pommey S., Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
12. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G.A., Willemze R., Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006, 108:2114-2120.
13. Badillo A.T., Beggs K.J., Javazon E.H., Tebbets J.C., Flake A.W. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral immune response. Biol Blood Marrow Transplant 2007, 13:412-422.
14. Poncelet A.J., Vercruysse J., Saliez A., Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007, 83:783-790.
15. Sudres M., Norol F., Trenado A., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006, 176:7761-7767.
16. Ankrum J., Karp J.M. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010, 16:203-209.
17. Mestas J., Hughes C.C. Of mice and men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
18. Isakova I.A., Phinney D.G. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 2005, 11:1255-1265.
19. Cserr H.F., Harling-Berg C.J., Knopf P.M. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 1992, 2:269-276.
20. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001, 36:118-124.
21. Stonestreet B.S., Patlak C.S., Pettigrew K.D., Reilly C.B., Cserr H.F. Ontogeny of blood-brain barrier function in ovine fetuses, lambs, and adults. Am J Physiol 1996, 271:1594-1601.
22. Engelhardt B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des 2008, 14:1555-1565.
23. Phillips L.M., Lampson L.A. Site-specific control of T cell traffic in the brain: T cell entry to brainstem vs. hippocampus after local injection of IFN-gamma. J Neuroimmunol 1999, 96:218-227.
24. Becher B., Prat A., Antel J.P. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000, 29:293-304.
25. Rock R.B., Gekker G., Hu S., et al. Role of microglia in central nervous system infections. Clin Microbiol Rev 2004, 17:942-964.
26. Isakova I.A., Baker K., Dufour J., Gaupp D., Phinney D.G. Preclinical evaluation of adult stem cell engraftment and toxicity in the CNS of rhesus macaques. Mol Ther 2006, 13:1173-1184.
27. Isakova I.A., Baker K., Dutreil M., Dufour J., Gaupp D., Phinney D.G. Age- and dose-related effects on MSC engraftment levels and anatomical distribution in the central nervous systems of nonhuman primates: identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 2007, 25:3261-3270.
28. + T cell epitopes. Immunogenetics 2007, 59:693-703.
29. Fortman J.D., Hewett T.A., Bennett B.T. The laboratory nonhuman primate 2002, CRC Press, Boca Raton, FL.
30. Doxiadis, Smits J.M., Schreuder G.M., et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996, 348:850-853.
31. Claas F.H., Dankers M.K., Oudshoorn M., et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transplant Immunol 2005, 14:187-191.
32. Rasmusson I., Uhlin M., Le Blanc K., Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007, 82:887-893.
33. Devine S.M., Bartholomew A.M., Mahmud N., et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001, 29:244-255.
34. Beggs K.J., Lyubimov A., Borneman J.N., et al. Immunological consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006, 15:711-721.
35. Cabellero A., Fernandez N., Lavado R., Bravo M.J., Miranda J.M., Alonso A. Tolerogenic response: allorecognition pathways. Transplant Immunol 2006, 17:3-6.
36. Whitelegg A., Barber L.D. The structural basis of T-cell allorecognition. Tissue Antigens 2004, 63:101-108.
37. Sherman L.A., Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993, 11:385-402.
38. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001, 166:973-981.
39. Gudmundsdottir H., Turka L.A. T-cell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol 1999, 10:1356-1365.
40. Sundin M., Barrett J.A., Ringden O., et al. HSCT recipients have specific tolerance to MSC but not the MSC donor. J Immunother 2009, 32:755-764.
41. Klyushnenkova E., Mosca J.D., Zernetkina V., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12:47-57.
42. Devine S.M., Cobbs C., Jennings M., Bartholomew A., Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101:2999-3001.
43. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 230:225-274.
44. Bix M., Liao N.-S., Zijlstra M., Loring J., Jaenisch R., Raulet D. Rejection of class I MHC deficient hematopoietic cells by irradiated MHC-mismatched mice. Nature 1991, 349:329-331.
45. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta I. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2 induced NK-cell proliferation. Blood 2006, 107:1484-1490.
46. + T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med 1985, 162:2089-2106.
47. +) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol 2008, 181:4219-4228.
48. Rutjens E., Mazza S., Biassoni R., et al. CD8(+) NK cells are predominant in chimpanzees and characterized by high NCR expression and cytokine production and preserved in chronic HIV-1 infection. Eur J Immunol 2010, 40:1440-1450.